• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis.

作者信息

Vreugdenhil G, Swaak A J, de Jeu-Jaspers C, van Eijk H G

出版信息

Ann Rheum Dis. 1990 Nov;49(11):956-7. doi: 10.1136/ard.49.11.956-b.

DOI:10.1136/ard.49.11.956-b
PMID:2256752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1004279/
Abstract
摘要

相似文献

1
Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis.口服铁螯合剂1,2-二甲基-3-羟基吡啶-4-酮（L1）与转铁蛋白之间的铁交换相关性以及L1在类风湿性关节炎中的可能抗贫血作用。
Ann Rheum Dis. 1990 Nov;49(11):956-7. doi: 10.1136/ard.49.11.956-b.
2
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.口服铁螯合剂L1对类风湿性关节炎贫血患者的疗效及安全性
Lancet. 1989 Dec 9;2(8676):1398-9. doi: 10.1016/s0140-6736(89)92011-4.
3
New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.口服L1（去铁酮）及其他螯合剂进行铁和铝螯合治疗的新概念。综述
Analyst. 1995 Mar;120(3):845-51. doi: 10.1039/an9952000845.
4
Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）在镰状细胞病铁过载患者中的铁平衡及剂量反应研究
Blood. 1994 Apr 15;83(8):2329-33.
5
Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Ann N Y Acad Sci. 1990;612:369-77. doi: 10.1111/j.1749-6632.1990.tb24324.x.
6
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）治疗重型地中海贫血的疗效及可能的不良反应
Blood. 1992 Aug 1;80(3):593-9.
7
Oral iron-chelating therapy: the L1 experience.口服铁螯合疗法：L1经验
Baillieres Clin Haematol. 1994 Dec;7(4):941-63. doi: 10.1016/s0950-3536(05)80132-5.
8
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.接受口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮或去铁胺治疗的铁过载患者的锌浓度。
J Clin Pathol. 1994 Jul;47(7):657-60. doi: 10.1136/jcp.47.7.657.
9
Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.口服铁螯合剂L1用于依赖输血的地中海贫血的疗效和安全性长期评估：印度试验
Br J Haematol. 1992 Oct;82(2):460-6. doi: 10.1111/j.1365-2141.1992.tb06445.x.
10
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）的长期试验。I. 铁螯合与代谢研究。
Br J Haematol. 1990 Oct;76(2):295-300. doi: 10.1111/j.1365-2141.1990.tb07887.x.

引用本文的文献

1
The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.去铁酮在将地中海贫血从致命疾病转变为慢性疾病过程中所起的关键作用及其在非铁过载疾病中重新应用面临的挑战
Pharmaceuticals (Basel). 2023 Jul 18;16(7):1016. doi: 10.3390/ph16071016.
2
New developments and controversies in iron metabolism and iron chelation therapy.铁代谢与铁螯合疗法的新进展及争议
World J Methodol. 2016 Mar 26;6(1):1-19. doi: 10.5662/wjm.v6.i1.1.
3
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016.
4
Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.通过保守重定位蓄积的金属来挽救铁过载的巨噬细胞。
Br J Pharmacol. 2011 Sep;164(2b):406-18. doi: 10.1111/j.1476-5381.2010.01120.x.

本文引用的文献

1
Effect of a specific iron chelating agent on animal models of inflammation.一种特定铁螯合剂对炎症动物模型的影响。
Ann Rheum Dis. 1983 Feb;42(1):89-93. doi: 10.1136/ard.42.1.89.
2
Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases.来自受刺激多形核白细胞产生的超氧化物介导铁蛋白中铁的动员。炎症性疾病中的可能机制。
J Clin Invest. 1984 Jun;73(6):1576-9. doi: 10.1172/JCI111364.
3
The measurement of reticuloendothelial iron release using iron-dextran.
Br J Haematol. 1971 Dec;21(6):617-22. doi: 10.1111/j.1365-2141.1971.tb02724.x.
4
The anaemia of chronic disorders.慢性病性贫血
Br J Haematol. 1971 Aug;21(2):147-52. doi: 10.1111/j.1365-2141.1971.tb03424.x.
5
Formation of hydroxyl radicals in the presence of ferritin and haemosiderin. Is haemosiderin formation a biological protective mechanism?铁蛋白和含铁血黄素存在时羟基自由基的形成。含铁血黄素的形成是一种生物保护机制吗？
Biochem J. 1986 Mar 15;234(3):727-31. doi: 10.1042/bj2340727.
6
Treatment of rheumatoid arthritis with desferrioxamine.用去铁胺治疗类风湿性关节炎。
Q J Med. 1986 Dec;61(236):1153-8.
7
Antianemic and potential anti-inflammatory activity of desferrioxamine: possible usefulness in rheumatoid arthritis.去铁胺的抗贫血及潜在抗炎活性：在类风湿关节炎中的可能用途
Clin Exp Rheumatol. 1986 Jan-Mar;4(1):25-9.
8
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.口服螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮对β地中海贫血中铁的有效螯合作用
Br Med J (Clin Res Ed). 1987 Dec 12;295(6612):1509-12. doi: 10.1136/bmj.295.6612.1509.
9
Investigation of the anti-inflammatory properties of hydroxypyridinones.羟基吡啶酮的抗炎特性研究。
Ann Rheum Dis. 1989 May;48(5):382-8. doi: 10.1136/ard.48.5.382.
10
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.口服铁螯合剂L1对类风湿性关节炎贫血患者的疗效及安全性
Lancet. 1989 Dec 9;2(8676):1398-9. doi: 10.1016/s0140-6736(89)92011-4.